PATENT CLAIM ANALYSIS

Application Number: 16128312
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "001000"]

Abstract:
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Claim (Index 39):
The high-load solid tablet formulation of any one of  claims 1 - 5 , wherein the formulation comprises intragranular and extragranular excipients; and the intragranular excipients comprise lactose, sodium lauryl sulfate, polyvinylpyrrolidone and croscarmellose sodium; and the extragranular excipients comprise croscarmellose sodium, sodium lauryl sulfate, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.

Metadata:
- Claim Count in Document: 89.0
- Percentile: 97.0
- Lexical Diversity: 1.51923
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15060010', '15909779', '15462444', '14821290', '15970721']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7553855516362991
- 35 USC 102 Novelty (BERT): 0.6126831723866256
- Combined Prediction Score: 0.7411153137113318
- Mean Citation Score: 457.25797400000016
- Max Citation Score: 556.6536
- Similarity Product: 475.9401657829284

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test